Skip to main content

07.12.2016 | original report

ASCO update 2016: colorectal cancer

verfasst von: Wolfgang Eisterer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Summary

At this year’s annual meeting of the American Society of Clinical Oncology, held during 3–7 June 2016 in Chicago, USA, investigators discussed the latest findings in colorectal cancer research. The main topics were immune checkpoint inhibition therapy in colorectal cancer and the prognostic and predictive influence of sidedness in the primary tumor location.
Literatur
1.
Zurück zum Zitat Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O’Neil J, Shaw JE, Atkins JN, Horvath LE, Polite BN, Meyerhardt JA, O’Reilly EM, Goldberg RM, Hochster HS, Blanke CD, Schilsky RL, Mayer RJ, Bertagnolli MM, Lenz H‑J. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(suppl):abstr 3504.CrossRef Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O’Neil J, Shaw JE, Atkins JN, Horvath LE, Polite BN, Meyerhardt JA, O’Reilly EM, Goldberg RM, Hochster HS, Blanke CD, Schilsky RL, Mayer RJ, Bertagnolli MM, Lenz H‑J. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(suppl):abstr 3504.CrossRef
2.
Zurück zum Zitat Venook AP, Niedzwiecki D, Lenz H‑J, Innocenti F, Mahoney MR, O’Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32(suppl):abstr LBA3.CrossRef Venook AP, Niedzwiecki D, Lenz H‑J, Innocenti F, Mahoney MR, O’Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32(suppl):abstr LBA3.CrossRef
3.
Zurück zum Zitat Heinemann V, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S‑E, Heintges T, Lerchenmuller CA, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen CA, Jung A, Kirchner T, Stintzing S. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol. 2014;32(suppl):abstr 3600.CrossRef Heinemann V, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S‑E, Heintges T, Lerchenmuller CA, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen CA, Jung A, Kirchner T, Stintzing S. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol. 2014;32(suppl):abstr 3600.CrossRef
4.
Zurück zum Zitat Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Wong R, Kosmider S, Tran B, Desai T, Hayes TM, Haydon AM, Yip D, Christie M, Strausberg R, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers. J Clin Oncol. 2016;34(suppl):abstr 3511.CrossRef Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Wong R, Kosmider S, Tran B, Desai T, Hayes TM, Haydon AM, Yip D, Christie M, Strausberg R, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers. J Clin Oncol. 2016;34(suppl):abstr 3511.CrossRef
5.
Zurück zum Zitat Overman MJ, Kopetz S, McDermott RS, Leach J, Lonardi S, Lenz H‑J, Morse MA, Desai J, Hill A, Axelson MD, Moss RA, Lin C‑S, Goldberg M, Andre T. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol. 2016;34(suppl):abstr 3501.CrossRef Overman MJ, Kopetz S, McDermott RS, Leach J, Lonardi S, Lenz H‑J, Morse MA, Desai J, Hill A, Axelson MD, Moss RA, Lin C‑S, Goldberg M, Andre T. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol. 2016;34(suppl):abstr 3501.CrossRef
6.
Zurück zum Zitat Bendell JC, Kim TW, Goh BC, Wallin J, Oh D‑Y, Han S‑W, Lee CB, Hellmann MD, Desai J, Lewin JH, Solomon BJ, Chow LQM, Miller WH, Gainor JF, Flaherty K, Infante JR, Das-Thakur M, Foster P, Cha E, Bang Y‑J. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). J Clin Oncol. 2016;34(suppl):abstr 3502.CrossRef Bendell JC, Kim TW, Goh BC, Wallin J, Oh D‑Y, Han S‑W, Lee CB, Hellmann MD, Desai J, Lewin JH, Solomon BJ, Chow LQM, Miller WH, Gainor JF, Flaherty K, Infante JR, Das-Thakur M, Foster P, Cha E, Bang Y‑J. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). J Clin Oncol. 2016;34(suppl):abstr 3502.CrossRef
7.
Zurück zum Zitat Le DT, Uram JN, Wang H, Bartlett B, kemberling H, Eyring A, Azad NS, Laheru D, Donehower RC, Crocenzi TS, Goldberg RM, Fisher GA, Lee JJ, Greten TF, Koshiji M, Kang SMP, Anders RA, Eshleman JR, Vogelstein B, Diaz LA. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. J Clin Oncol. 2016;34(suppl):abstr 103.CrossRef Le DT, Uram JN, Wang H, Bartlett B, kemberling H, Eyring A, Azad NS, Laheru D, Donehower RC, Crocenzi TS, Goldberg RM, Fisher GA, Lee JJ, Greten TF, Koshiji M, Kang SMP, Anders RA, Eshleman JR, Vogelstein B, Diaz LA. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. J Clin Oncol. 2016;34(suppl):abstr 103.CrossRef
8.
Zurück zum Zitat Raghav RPS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, Muranyi A, Singh S, Routbort M, Chen K, Shaw KR, Shannmugam K, Maru DM, Fakih M, Kopetz S. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol. 2016;34(suppl):abstr 3517.CrossRef Raghav RPS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, Muranyi A, Singh S, Routbort M, Chen K, Shaw KR, Shannmugam K, Maru DM, Fakih M, Kopetz S. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol. 2016;34(suppl):abstr 3517.CrossRef
9.
Zurück zum Zitat Siena S, Sartore-Bianchi A, Lonardi S, Trusolino L, Martino C, Bencardino K, Leone F, Zagonel V, Valtorta E, Torri V, Siravegna G, Amatu A, Bonazzina EF, Rusconi F, Ghezzi S, Ciardiello F, Veronese S, Comoglio PM, Bardelli A, Marsoni S. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol. 2015;33(suppl):abstr 3508.CrossRef Siena S, Sartore-Bianchi A, Lonardi S, Trusolino L, Martino C, Bencardino K, Leone F, Zagonel V, Valtorta E, Torri V, Siravegna G, Amatu A, Bonazzina EF, Rusconi F, Ghezzi S, Ciardiello F, Veronese S, Comoglio PM, Bardelli A, Marsoni S. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol. 2015;33(suppl):abstr 3508.CrossRef
Metadaten
Titel
ASCO update 2016: colorectal cancer
verfasst von
Wolfgang Eisterer
Publikationsdatum
07.12.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0298-9

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.